# Neuropsychiatric Systemic Lupus Erythematosus Diagnosed Following Treatment Initiated for Acute Encephalitis

**Authors:** Keidai Kumazawa, Norio Nakagawa, Koichi Tanda, Yasuko Okumura, Akira Nishimura

PMC · DOI: 10.7759/cureus.102396 · Cureus · 2026-01-27

## TL;DR

A 14-year-old girl initially suspected of having encephalitis was later diagnosed with neuropsychiatric systemic lupus erythematosus after showing persistent symptoms and lab findings.

## Contribution

The case highlights the diagnostic challenge of NP-SLE when it presents similarly to anti-NMDA receptor encephalitis.

## Key findings

- NP-SLE can present with status epilepticus and fever, mimicking anti-NMDA receptor encephalitis.
- Persistent renal dysfunction and cytopenia led to the correct diagnosis of NP-SLE.
- Measuring ANA and complement levels can aid in differentiating NP-SLE from similar conditions.

## Abstract

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by diverse clinical manifestations. This case report describes a 14-year-old female patient diagnosed with neuropsychiatric SLE (NP-SLE) following status epilepticus. The patient was a 14-year-old previously healthy female and was transported to the emergency department owing to fever and status epilepticus. Based on imaging findings, clinical findings, and the patient's age, anti-N-methyl-D-aspartate (NMDA) receptor encephalitis (NMDARE) was suspected, and intensive care was initiated. However, persistent renal dysfunction and cytopenia prompted detailed investigation, leading to a diagnosis of NP-SLE. SLE is a systemic disease requiring long-term treatment. In such cases, where characteristic rashes are absent, differential diagnosis based on physical findings is difficult. Although NP-SLE and NMDARE share many standard features, including clinical symptoms and age of onset, measuring antinuclear antibody (ANA) and complement levels may be valuable in the differential diagnosis.

## Linked entities

- **Diseases:** systemic lupus erythematosus (MONDO:0007915), anti-NMDA receptor encephalitis (MONDO:0021081)

## Full-text entities

- **Genes:** HP (haptoglobin) [NCBI Gene 3240] {aka HP2ALPHA2, HPA1S}, GRIN1 (glutamate ionotropic receptor NMDA type subunit 1) [NCBI Gene 2902] {aka DEE101, GluN1, MRD8, NDHMSD, NDHMSR, NMD-R1}, GRIN2B (glutamate ionotropic receptor NMDA type subunit 2B) [NCBI Gene 2904] {aka DEE27, EIEE27, GluN2B, MRD6, NMDAR2B, NR2B}, GRIN2A (glutamate ionotropic receptor NMDA type subunit 2A) [NCBI Gene 2903] {aka EPND, FESD, GluN2A, LKS, NMDAR2A, NR2A}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** fever (MESH:D005334), proteinuria (MESH:D011507), neurological symptoms (MESH:D009461), Small vessel disease (MESH:D059345), clonic seizures (MESH:D012640), status epilepticus (MESH:D013226), Lupus (MESH:D008180), autoimmune (MESH:D001327), Vasogenic edema (MESH:D001929), rash (MESH:D005076), microangiopathy (MESH:D014652), -NMDA receptor antibody encephalitis (MESH:D060426), lupus nephritis (MESH:D008181), medial temporal lobe lesions (MESH:D004833), ovarian teratoma (MESH:C562731), psychiatric (MESH:D001523), neurotoxicity (MESH:D020258), NP-SLE (MESH:D020945), edema (MESH:D004487), neuroinflammation (MESH:D000090862), vasculitis (MESH:D014657), disease (MESH:D004194), inflammation (MESH:D007249), headache (MESH:D006261), autoimmune encephalitides (MESH:D020274), influenza (MESH:D007251), Hematuria (MESH:D006417), Central nervous system infections (MESH:D002494), memory deficits (MESH:D008569), infectious diseases (MESH:D003141), Coma (MESH:D003128), cognitive impairment (MESH:D003072), renal dysfunction (MESH:D007674), systemic (MESH:D015619), TMA (MESH:D057049), acute psychosis (MESH:D011605), COVID-19 (MESH:D000086382), thrombocytopenia (MESH:D013921), organic brain disorder (MESH:D019965), Encephalitis (MESH:D004660), thrombosis (MESH:D013927), anemia (MESH:D000740), mesangial proliferative glomerulonephritis (MESH:D005921), cytopenia (MESH:D006402), impaired consciousness (MESH:D003244), brain dysfunction (MESH:D001927), complement deficiency (MESH:D007153)
- **Chemicals:** N-methyl-D-aspartate (MESH:D016202), cyclophosphamide (MESH:D003520), methylprednisolone (MESH:D008775), edaravone (MESH:D000077553), fentanyl (MESH:D005283), mycophenolate mofetil (MESH:D009173), oxygen (MESH:D010100), thiopental (MESH:D013874), midazolam (MESH:D008874), creatinine (MESH:D003404), mannitol (MESH:D008353), rituximab (MESH:D000069283), dexmedetomidine (MESH:D020927), NMDA (-), hydroxychloroquine (MESH:D006886)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12947955/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12947955/full.md

## References

15 references — full list in the complete paper: https://tomesphere.com/paper/PMC12947955/full.md

---
Source: https://tomesphere.com/paper/PMC12947955